GEN Exclusives

More »

GEN News Highlights

More »
Oct 6, 2006

Microsomal Triglyceride Transfer Protein Inhibitors Patents Cross-licensed

  • Aegerion Pharmaceuticals in collaboration with Pfizer and the University of Pennsylvania entered into a cross-license relationship covering a range of patents related to the use of microsomal triglyceride transfer protein (MTP) inhibitors.

    Based on the terms of the agreement, Aegerion can independently pursue product-development opportunities involving potential MTP-based therapies to reduce LDL cholesterol. MTP inhibitors have been proven effective in reducing LDL levels in men and women, according to the companies, and are being studied for potential use as monotherapies or in combination with statins or other therapies to reduce LDL cholesterol levels.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?